Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma
JCO Oncology Practice · 2025
DOI: 10.1200/op.24.00277 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Joseph G Schroers-Martin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
Classic Hodgkin lymphoma (cHL) is highly curable at all stages. Research efforts over the past few decades have largely focused on interim PET-adapted strategies for therapy de-escalation or intensification. The overarching goals have been to increase cure rates, minimize potential therapy-related effects, and optimize survivorship. Better understanding of the biology of cHL has led to the development and approval of effective novel agents including the antibody-drug conjugate brentuximab vedotin and the checkpoint inhibitor immunotherapies. In this review, we discuss recent trial results and how these agents are integrated into clinical practice with the goal of further optimizing outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA.
ORCID-Profile: Joseph G Schroers-Martin, Ranjana Advani
Zitieren
APA
Schroers-Martin, J. G., & Advani, R. (2025). Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma. JCO Oncology Practice. https://doi.org/10.1200/op.24.00277
Vancouver
Schroers-Martin JG, Advani R. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma. JCO Oncology Practice. 2025. doi:10.1200/op.24.00277
BibTeX
@article{SchroersMartin2025,
author = {Schroers-Martin, Joseph G and Advani, Ranjana},
title = {Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma},
journal = {JCO Oncology Practice},
year = {2025},
doi = {10.1200/op.24.00277}
}
EUVIMED